ArticleThe Journal of international medical research2025
Association of TLR3 1337C/T and 1234C/T polymorphisms with chronic hepatitis B virus infection in Sudanese patients: A case-control study.
Article in The Journal of international medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ObjectiveThis study aimed to investigate the association of TLR3 single-nucleotide polymorphisms 1337 C/T (rs3775290) and 1234 C/T (rs3775291) with the risk of chronic hepatitis B virus infection.MethodsThis case-control study enrolled 136 participants (66 patients with chronic hepatitis B virus infection (cases) and 70 healthy controls). TLR3 polymorphisms were genotyped using polymerase chain reaction-restriction fragment length polymorphism. Demographic/clinical data were collected via standardized questionnaires and analyzed using Statistical Package for Social Sciences (significance level: p < 0.05).ResultsFor TLR3 1337 C/T polymorphism, the CT genotype prevalence was significantly higher in cases (47.0%) than in controls (31.4%) (odds ratio = 0.42, 95% confidence interval: 0.20-0.87, p = 0.0187), while the CC genotype demonstrated protective effects (39.4% in cases vs. 62.9% in controls; odds ratio = 0.26, 95% confidence interval: 0.07-0.94, p = 0.0314). The C allele frequency showed significant between-group differences (odds ratio = 0.46, p = 0.0044). No associations were observed for 1234 C/T single-nucleotide polymorphism (p = 1.0). Biochemical analysis revealed significantly elevated alanine aminotransferase (p = 0.0044) and aspartate aminotransferase (p < 0.0001) levels in cases than in controls.ConclusionsRegarding TLR3 1337 C/T single-nucleotide polymorphism, the CT genotype increases the risk of chronic hepatitis B virus infection (odds ratio = 0.42), while the CC genotype demonstrates protective effects (odds ratio = 0.26) in Sudanese populations, suggesting its utility as a therapeutic target and prognostic marker. No 1234 C/T associations were observed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.